 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...158159160161162163164165166167168...208209» |
- ||| AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment open: A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC (clinicaltrials.gov) - Feb 21, 2021
P2, N=150, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Apatinib Promotes Ferroptosis in Colorectal Cancer Cells by Targeting ELOVL6/ACSL4 Signaling. (Pubmed Central) - Feb 20, 2021
Moreover, ACSL4, a vital regulator of ferroptosis, could interact with ELOVL6 directly, which was confirmed by the result of co-IP. These findings demonstrated that apatinib promoted ferroptosis in CRC cells by targeting ELOVL6/ACSL4, providing a new mechanism support for apatinib application in the clinical treatment of CRC.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
Enrollment change, IO biomarker: Efficacy and Safety of Sintilimab and Apatinib Combined Chemotherapy in Breast Cancer (clinicaltrials.gov) - Feb 19, 2021
P2, N=34, Recruiting, Sponsor: Jiuda Zhao
These findings demonstrated that apatinib promoted ferroptosis in CRC cells by targeting ELOVL6/ACSL4, providing a new mechanism support for apatinib application in the clinical treatment of CRC. N=26 --> 34
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
New P2 trial: TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN) (clinicaltrials.gov) - Feb 18, 2021
P2, N=120, Not yet recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
- || Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharma
Clinical, PK/PD data, Journal: Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects. (Pubmed Central) - Feb 18, 2021
Among the subjects, oral administration of 400 mg of flumatinib was safe and well tolerated. High-fat diet significantly increases the exposure to flumatinib, therefore, fasting may be recommended.
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
New trial, Heterogeneity, Metastases: 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response (clinicaltrials.gov) - Feb 15, 2021
P, N=30, Completed, Sponsor: Biyun Wang, MD
- || AiTan (rivoceranib) / HLB Bio Group
Biomarker, Clinical, Journal: Adipose tissue area as a predictor for the efficacy of apatinib in platinum-resistant ovarian cancer: an exploratory imaging biomarker analysis of the AEROC trial. (Pubmed Central) - Feb 12, 2021
P2
High areas of VAT, SAT, and IMAT were significantly associated with better outcomes in patients with platinum-resistant or platinum-refractory ovarian cancer who received VEGFR inhibitors. AT assessments may be valuable as patient-specific imaging biomarkers for predicting response to VEGFR inhibitors.
- ||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
I’m glad this time #pyrotinib was compared to another her2 agent. I remember being 😱 at #asco19 when the control arm of the pyro study didn’t target Her2 AT ALL! 1/2 (Twitter) - Feb 12, 2021
- || Kadcyla (ado-trastuzumab emtansine) / Roche, pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine
Clinical, Journal, Real-World Evidence: Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study. (Pubmed Central) - Feb 12, 2021
The percentages of grade 3 to 4 AEs in the pyrotinib and T-DM1 groups were 34.5% and 40.0%, respectively. The results of this study suggest that patients with HER2-positive MBC with trastuzumab and lapatinib failure can benefit from subsequent pyrotinib treatment and tolerate this treatment well, especially those who have benefited from previous lapatinib treatment or those who have no liver metastasis.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial: A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy (clinicaltrials.gov) - Feb 10, 2021
P2, N=42, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trial completion date, Trial primary completion date: A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer (clinicaltrials.gov) - Feb 10, 2021
P2, N=40, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
The results of this study suggest that patients with HER2-positive MBC with trastuzumab and lapatinib failure can benefit from subsequent pyrotinib treatment and tolerate this treatment well, especially those who have benefited from previous lapatinib treatment or those who have no liver metastasis. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Jun 2021
- || AiRuiKa (camrelizumab) / HLB Bio Group
Trial initiation date: NEOPBOSCC: Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 10, 2021
P2, N=108, Not yet recruiting, Sponsor: Hospital of Stomatology, Wuhan University
Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2020 --> Jun 2021 Initiation date: Dec 2020 --> Mar 2021
- ||||| FDA event, Orphan drug: The FDA grants Orphan Drug Designation to Apatinib for the treatment of #ACC Drugs like #Lenvatinib (Lenvima), #Axitinib (Inlyta), AL101 #NOTCH1 Inhibitors are showing some success. https://t.co/wPRj6jUQCZ @JAMAOnc @MDAndersonNews @HeadNeckMD @sloan_kettering @Carlavanherpen (Twitter) - Feb 9, 2021
- || AiRuiKa (camrelizumab) / Incyte
Clinical, P1 data, Journal: A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. (Pubmed Central) - Feb 9, 2021
P1
Camrelizumab has manageable toxicity and encouraging preliminary antitumor activity in advanced solid tumors in Australia. ClinicalTrials.gov Identifier: NCT02492789.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma. (Pubmed Central) - Feb 9, 2021
Seven patients received dose adjustment of apatinib due to side effects. In patients with pulmonary and/or hepatic metastases of NPC, low-dose apatinib plus S-1 yielded an excellent survival benefit, and the toxicities were mild and tolerable.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer. (Pubmed Central) - Feb 9, 2021
Patients with advanced gastric cancer achieve relatively satisfactory short-term therapeutic effects after treatment with apatinib combined with S-1 in the third-line therapy, whose PFS is notably better than those treated with S-1 alone, and they are tolerant to adverse reactions. Highly differentiated tumors and post-treatment proteinuria and hand-foot syndrome are predictable factors for the PFS of patients.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Leiomyosarcoma After Liver Transplantation Is Unrelated to Epstein-Barr Virus: A Case Report. (Pubmed Central) - Feb 9, 2021
Highly differentiated tumors and post-treatment proteinuria and hand-foot syndrome are predictable factors for the PFS of patients. De novo leiomyosarcoma is a rare but serious event after LT, needing comprehensive management.
- ||| AiTan (rivoceranib) / HLB Bio Group
Orphan drug: #ElevarTherapeutics Announces #OrphanDrugDesignation for #Rivoceranib (#Apatinib) for the Treatment of #AdenoidCysticCarcinoma (ACC) https://t.co/bTIqCcUZ3u (Twitter) - Feb 9, 2021
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Addition of apatinib to transarterial chemoembolization leads to improved outcome in patients with intermediate and advanced hepatocellular cancer. (Pubmed Central) - Feb 9, 2021
De novo leiomyosarcoma is a rare but serious event after LT, needing comprehensive management. No abstract available
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
Enrollment open: Impact of Remimazolam on Prognosis After Bladder Cancer Surgery (clinicaltrials.gov) - Feb 9, 2021
P4, N=1128, Recruiting, Sponsor: Peking University First Hospital
No abstract available Not yet recruiting --> Recruiting
- ||| SHR-1707 / Jiangsu Hengrui Pharma
New P1 trial: A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects (clinicaltrials.gov) - Feb 8, 2021
P1, N=62, Not yet recruiting, Sponsor: Atridia Pty Ltd.
- | AiTan (rivoceranib) / HLB Bio Group
Enrollment change, Trial termination: Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC (clinicaltrials.gov) - Feb 8, 2021
P2, N=37, Terminated, Sponsor: Fuzhou General Hospital
Not yet recruiting --> Recruiting N=135 --> 37 | Recruiting --> Terminated; Due to the enrollment was slow and exceeded the expected enrollment time
- |||| AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov) - Feb 8, 2021
P3, N=56, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=135 --> 37 | Recruiting --> Terminated; Due to the enrollment was slow and exceeded the expected enrollment time Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. (clinicaltrials.gov) - Feb 7, 2021
P3, N=45, Recruiting, Sponsor: Fuzhou General Hospital
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | paclitaxel / Generic mfg.
Journal: Progress in conversion therapy for stage IV gastric cancer (Pubmed Central) - Feb 5, 2021
Gastric cancer is a malignant tumor with high heterogeneity, the classification of stage IV gastric cancer represented by Yoshida classification is based on imaging, and a more reasonable classification method should be developed in combination with gene detection in the future. Based on this, an individualized and accurate conversion therapy plan is formulated, so as to effectively improve the long-term survival of patients with stage IV gastric cancer.
- || zeprumetostat (SHR-2554) / Treeline Biosci
Enrollment change, Trial completion date, Trial primary completion date: A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms (clinicaltrials.gov) - Feb 5, 2021
P1, N=120, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Based on this, an individualized and accurate conversion therapy plan is formulated, so as to effectively improve the long-term survival of patients with stage IV gastric cancer. N=42 --> 120 | Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2022
- || edralbrutinib (TG-1701) / TG Therap
Enrollment closed, Trial completion date, Trial primary completion date: Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor (clinicaltrials.gov) - Feb 5, 2021
P1, N=86, Active, not recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
N=42 --> 120 | Trial completion date: Sep 2020 --> Jun 2023 | Trial primary completion date: Sep 2020 --> Jun 2022 Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Sep 2022 | Trial primary completion date: Dec 2018 --> Jun 2022
- | zeprumetostat (SHR-2554) / Treeline Biosci, AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment change, Trial completion date, Trial termination: A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC (clinicaltrials.gov) - Feb 5, 2021
P1/2, N=9, Terminated, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Sep 2022 | Trial primary completion date: Dec 2018 --> Jun 2022 N=100 --> 9 | Trial completion date: Jul 2021 --> Dec 2020 | Recruiting --> Terminated; According to the available data from the trial?the sponsor determined to terminate this study.
- | Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
New trial, Real-world evidence, Real-world: HS-2020-07SZ: Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Feb 4, 2021
P, N=420, Recruiting, Sponsor: The First Affiliated Hospital of Soochow University
- | AiRuiKa (camrelizumab) / HLB Bio Group
New trial: Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery (clinicaltrials.gov) - Feb 4, 2021
P=N/A, N=20, Recruiting, Sponsor: Fuzhou General Hospital
- | AiTan (rivoceranib) / HLB Bio Group
Journal: Enhancing the chemotherapy effect of Apatinib on gastric cancer by co-treating with salidroside to reprogram the tumor hypoxia micro-environment and induce cell apoptosis. (Pubmed Central) - Feb 4, 2021
Underlying mechanisms were further investigated and it was revealed that the anti-gastric cancer effect of Apa was signally improved by Sal through down-regulation the proliferation factors and increase the pro-apoptotic genes, as well as reprograming the tumor hypoxia micro-environment. In a word, the study showed that the Sal was able of improving the chemosensitivity of gastric cancer to Apa and the iVR1-NPs-Apa/Sal was capable of realizing highly efficient of tumor-targeting drug delivery.
- | ifosfamide / Generic mfg., methotrexate / Generic mfg.
Journal: Current Treatment Considerations for Osteosarcoma Metastatic at Presentation. (Pubmed Central) - Feb 4, 2021
Standard chemotherapy for osteosarcoma metastatic at presentation is based on high-dose methotrexate, doxorubicin, and cisplatin (the MAP regimen), with the possible addition of ifosfamide...Advanced radiotherapy techniques, such as carbon ion radiotherapy and stereotactic radiosurgery, and molecular targeted chemo-therapy with drugs such as pazopanib or apatinib have improved the dismal prognosis, especially for patients who are medically inoperable or who refuse surgery...[Orthopedics. 2020;43(x):xx-xx.].
- |||||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New P3 trial: Hetrombopag for Pediatric Patients With Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Feb 4, 2021
P3, N=117, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Apatinib as non-first-line treatment in patients with Intrahepatic Cholangiocarcinoma. (Pubmed Central) - Feb 4, 2021
P2
The most common grade 3 adverse events were hypertension (23.1%) and elevated transaminase (11.5%). Apatinib as non-first-line monotherapy has potential therapeutic efficacy in patients with advanced cholangiocarcinoma.
- | Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly, AiTan (rivoceranib) / Elevar Therapeutics
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC (clinicaltrials.gov) - Feb 3, 2021
P2, N=0, Withdrawn, Sponsor: Sun Yat-sen University
Apatinib as non-first-line monotherapy has potential therapeutic efficacy in patients with advanced cholangiocarcinoma. N=30 --> 0 | Trial completion date: Dec 2021 --> Feb 2021 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Feb 2021
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment change: Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 3, 2021
P1/2, N=46, Recruiting, Sponsor: Zhejiang Cancer Hospital
N=30 --> 0 | Trial completion date: Dec 2021 --> Feb 2021 | Recruiting --> Withdrawn | Trial primary completion date: Jul 2021 --> Feb 2021 N=26 --> 46
- || HRS4800 / Jiangsu Hengrui Pharma
Enrollment open: A Trial of HRS4800 Tables in Healthy Male Subjects (clinicaltrials.gov) - Feb 3, 2021
P1, N=50, Recruiting, Sponsor: Atridia Pty Ltd.
N=26 --> 46 Not yet recruiting --> Recruiting
- || hetrombopag (SHR 8735) / Jiangsu Hengrui Medicine
Clinical, Journal: Commentary on: First-in-patient study of hetrombopag in patients with chronic idiopathic thrombocytopenic purpura. (Pubmed Central) - Feb 3, 2021
Not yet recruiting --> Recruiting No abstract available
- || Sorry, second China approval for Tyvyt. Keytruda laso has 1L NSCLC label, Baizean $BGNE is approved for 1L squam NSCLC, and Ailituo/camrelizumab for 1L non-squam NSCLC. (Twitter) - Feb 3, 2021
- | Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
New P3 trial: Inetetamab Plus Rapamycin and Chemotherapy for HER2+ Metastatic Breast Cancer With Abnormal Activation of PAM Pathway (clinicaltrials.gov) - Feb 3, 2021
P3, N=270, Not yet recruiting, Sponsor: Peking Union Medical College
- ||||||| AiTan (rivoceranib) / HLB Bio Group
Trial completion, Trial completion date: Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP) (clinicaltrials.gov) - Feb 2, 2021
P3, N=400, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
No abstract available Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Feb 2020
- |||||| Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Enrollment open: A Study of Evaluating The Effects Of Pyrotinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (clinicaltrials.gov) - Feb 2, 2021
P3, N=1192, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Feb 2020 Not yet recruiting --> Recruiting
- ||| AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Trial completion date, Trial primary completion date: NIC-ESCC2019: Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 2, 2021
P2, N=56, Completed, Sponsor: Guangzhou Institute of Respiratory Disease
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Jun 2023 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021
- || AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
New P2 trial: A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer. (clinicaltrials.gov) - Feb 2, 2021
P2, N=35, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date: Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors (clinicaltrials.gov) - Jan 31, 2021
P1, N=50, Active, not recruiting, Sponsor: Hengrui Therapeutics, Inc.
Recruiting --> Completed | Trial completion date: Jun 2023 --> Jan 2021 | Trial primary completion date: May 2021 --> Jan 2021 Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Sep 2020 --> May 2021
- ||||| plinabulin (BPI 2358) / BeyondSpring
Enrollment closed, Trial completion date: DUBLIN-3: Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (clinicaltrials.gov) - Jan 31, 2021
P3, N=559, Active, not recruiting, Sponsor: BeyondSpring Pharmaceuticals Inc.
Trial completion date: Mar 2021 --> Jun 2021 | Trial primary completion date: Sep 2020 --> May 2021 Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Dec 2021
- || AiTan (rivoceranib) / HLB Bio Group
Clinical, Journal: Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial. (Pubmed Central) - Jan 30, 2021
P2
Recruiting --> Active, not recruiting | Trial completion date: Nov 2020 --> Dec 2021 Based on the data from this trial, we hope to identify a treatment plan that is suitable for female patients with TNBC, who have been treated with anthracyclines and taxanes, in Northeast China.
- ||| pyrotinib (SHR-1258) / Jiangsu Hengrui Medicine, Gilotrif (afatinib) / Boehringer Ingelheim
NSCLC with Her2 transmembrane domain V659E mutations Ziqi Jia #WCLC20 Incidence - 0.18% ORR- Targetted Rx ( pyrotinib>>Afatinib>>lapatinib) >> CT >> IO (Twitter) - Jan 30, 2021
- fluzoparib (SHR 3162) / Jiangsu Hengrui Medicine
[VIRTUAL] Fuzuloparib maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer: A multicenter, randomized, double-blind, placebo-controlled, phase III trial () - Jan 29, 2021 - Abstract #SGO2021SGO_932;
Objectives: Fuzuloparib (formerly fluzoparib), a poly (ADP-ribose) polymerase inhibitor, has shown promising antitumor activity and acceptable safety for the treatment of relapsed ovarian cancer patients harboring the BRCA 1/2 mutation after 2-4 lines of platinum-based chemotherapy in previous phase 2 trial... Fuzuloparib as maintenance therapy achieved a statistically significant and clinically meaningful improvement in PFS for patients with platinum-sensitive, relapsed ovarian cancer compared with placebo, regardless of BRCA 1/2 mutation, and had a manageable safety profile.
- AiTan (rivoceranib) / HLB Bio Group
[VIRTUAL] Apatinib combined with pegylated liposomal doxorubicin (PLD) versus PLD for platinum-resistant recurrent ovarian cancer (APPROVE): A multicenter, randomized, controlled, open-label, phase II trial () - Jan 29, 2021 - Abstract #SGO2021SGO_859;
ORR and DCR were also significantly improved. Adverse events were consistent with the established safety profiles of apatinib and PLD